Sen. Ossoff Working Across the Aisle to Lower Price of Medicine for Georgia Families

Washington, D.C. - U.S. Senator Jon Ossoff is working across the aisle to lower the price of life-saving medicine.

Sen. Ossoff recently cosponsored the bipartisan Biosimilar Red Tape Elimination Act to eliminate outdated regulations that often raise the price of critical medications for Georgia families.

The bill, first introduced by Sens. Mike Lee (R-UT) and Ben Ray Luján (D-NM), would streamline access to biosimilars, which are the "generic" versions of a class of medicine known as biologics. Under current law, even if a biosimilar is approved by the Food and Drug Administration (FDA), additional time-consuming studies are needed for it be deemed "interchangeable."

If a biologic drug is prescribed, even if there is a biosimilar available, doctors cannot offer it unless it has the "interchangeable" designation, increasing costs and creating confusion for both providers and patients.

In Georgia, generics and biosimilars saved Medicare enrollees an average of $2,750 per enrollee in 2022.

"Unnecessary red tape drives up costs and stands in the way of families receiving the life-saving medications they need,"Sen. Ossoff said. "I am working across the aisle to help ensure Georgians can afford critical treatments."

Sen. Ossoff continues working to lower drug costs for Georgians.

In March, Sen. Ossoff worked with Republicans and Democrats to pass the Increasing Transparency in Generic Drug Applications Act to increase transparency in generic drug applications and reduce unnecessary delays so that these low-cost medications are brought to consumers faster.

In 2023, Sen. Ossoff helped advance a package of bipartisan legislation - bringing together Democrats and Republicans to pass a fleet of bills dedicated to reducing these burdensome prescription drug costs for Georgians.

In 2022, Sen. Ossoff helped pass into law a bill that forced drug companies to negotiate lower prescription drug costs with Medicare, and lower costs for 10 drugs went into effect as of January 1, 2026.

Click here to read the Biosimilar Red Tape Elimination Act.

# # #